EUVIMEDOpdag EUVIMED
Crossref

Loss of SETD2‐mediated downregulation of intracellular and exosomal miRNA‐10b determines MAPK pathway activation and multidrug resistance in renal cancer

Libin Yan, Siyue Liu, Guoliang Sun, Beichen Ding, Zhize Wang, Heng Li

Molecular Carcinogenesis · 2023

DOI: 10.1002/mc.23614 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2023. Written by Libin Yan and 5 co-authors. Institution: Department of Urology, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China. Major MEDLINE topics: MicroRNAs, Histone-Lysine N-Methyltransferase, Kidney Neoplasms, Carcinoma, Renal Cell. Cited 3 times so far (Crossref); 32 references. Funded by: Key Program of Tongji Hospital research fund, National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

SET domain‐containing 2 (SETD2) is the most frequently mutated gene among all the histone methyltransferases in clear cell renal cell carcinoma (ccRCC). Microarrays, RNA sequencing analysis and exosomes analysis of cellular supernatant were performed after transfection A498 cells with si‐SETD2 or siRNA of negative control. Chromatin immunoprecipitation and Luciferase reporter assay were conducted to evaluate the interaction between SETD2 and miR‐10b. Functional and drug experiments in vitro and in vivo were performed to verify the role of SETD2, miR‐10b and MAP4K4. The results showed that loss of SETD2 mediated downregulation of intracellular and exosomal microRNA‐10b. MAP4K4 were relevant to oncogenesis of ccRCC caused by loss of SETD2 and miR‐10b. SETD2 could directly target miR‐10b and regulate the expression of multidrug resistance (MDR)‐1 (P‐gp170) through JNK pathway, which was one of the downstream pathways of MAP4K4. The coordinated expression of SETD2/H3K36me3/miR‐10b/MAPKs/JNK/MDR pathway was revealed to the progression of ccRCC.

Subjects

MeSH terms (MEDLINE)

MicroRNAsHistone-Lysine N-MethyltransferaseKidney NeoplasmsCarcinoma, Renal CellDrug Resistance, NeoplasmMAP Kinase Signaling SystemDrug Resistance, MultipleHumansGene Expression Regulation, NeoplasticExosomesDown-RegulationAnimalsCell Line, TumorMiceCell ProliferationMice, Nude

Author keywords

MDRSETD2ccRCCexosomemiRNAs

Substances

MicroRNAsSETD2 protein, humanHistone-Lysine N-MethyltransferaseMIRN10 microRNA, human

Authors and institutions

  • Department of Urology, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Endocrinology, School of Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University, Hangzhou, China.
  • Department of Urinary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

Funding

  • Key Program of Tongji Hospital research fund
  • National Natural Science Foundation of China

Cite

APA

Yan, L., Liu, S., Sun, G., Ding, B., Wang, Z., & Li, H. (2023). Loss of SETD2‐mediated downregulation of intracellular and exosomal miRNA‐10b determines MAPK pathway activation and multidrug resistance in renal cancer. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23614

Vancouver

Yan L, Liu S, Sun G, Ding B, Wang Z, Li H. Loss of SETD2‐mediated downregulation of intracellular and exosomal miRNA‐10b determines MAPK pathway activation and multidrug resistance in renal cancer. Molecular Carcinogenesis. 2023. doi:10.1002/mc.23614

BibTeX
@article{Yan2023,
  author = {Yan, Libin and Liu, Siyue and Sun, Guoliang and Ding, Beichen and Wang, Zhize and Li, Heng},
  title = {Loss of SETD2‐mediated downregulation of intracellular and exosomal miRNA‐10b determines MAPK pathway activation and multidrug resistance in renal cancer},
  journal = {Molecular Carcinogenesis},
  year = {2023},
  doi = {10.1002/mc.23614}
}
Start for free →